DES (drug-eluting stent) study finds Cypher to be more cost-effective than Taxus:
This article was originally published in Clinica
A German drug-eluting stent (DES) study has found that Johnson and Johnson's Cypher stent is more cost-effective than Boston Scientific's Taxus stent in patients at high risk of artery re-blockage. Sirolimus-eluting Cypher was associated with similar in-hospital costs, but significantly lower total costs at nine to 12 months compared with paclitaxel-eluting Taxus, according to the results, published in the Journal of the American College of Cardiology (July 18). "While health care costs and reimbursement rates vary between countries, these data suggest-that these cost differences are mainly due to the clinical benefits of the Cypher in reducing the need for a repeat procedure," said senior study author Dr Adnan Kastrati, of Deutsches Herzzentrum, in Munich. Specifically, total costs for Cypher and Taxus were Euro8,924 ($11,465) and Euro10,903, respectively.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.